for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Walvax Biotechnology Co Ltd

300142.SZ

Latest Trade

31.08CNY

Change

-0.52(-1.65%)

Volume

6,651,655

Today's Range

30.97

 - 

31.85

52 Week Range

17.69

 - 

33.28

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
31.60
Open
31.60
Volume
6,651,655
3M AVG Volume
338.07
Today's High
31.85
Today's Low
30.97
52 Week High
33.28
52 Week Low
17.69
Shares Out (MIL)
1,537.44
Market Cap (MIL)
46,246.11
Forward P/E
250.67
Dividend (Yield %)
0.10

Next Event

Walvax Biotechnology Co Ltd Annual Shareholders Meeting

Latest Developments

More

Shenzhen Exchange Filing Shows Block Trade Of Walvax Biotech's Shares Involving 146.1 Mln Yuan

Walvax Biotechnology To Sell Stake In Bio-Pharmaceutical Firm

Walvax Biotechnology's Unit Plans To Subscribe Shares In JHBP (CY) Holdings

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Walvax Biotechnology Co Ltd

Walvax Biotechnology Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of vaccines, monoclonal antibodies and blood products. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The Company distributes its products mainly in domestic market.

Industry

Biotechnology & Drugs

Contact Info

19F, Tower A, Building 9

Dingyi Tiancheng, No.99, Keyuan Road

Hi-Tech Zone

+86.871.68312779

http://www.walvax.com/

Executive Leadership

Yunchun Li

Chairman of the Board

Runsheng Jiang

President, Director

Zhen Huang

Vice Chairman of the Board

Hua Zhou

Chief Financial Officer

Yunyan Wu

Chief Operating Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

0.7K

2018

0.9K

2019(E)

1.1K
EPS (CNY)

2017

-0.349

2018

0.680

2019(E)

0.120
Price To Earnings (TTM)
43.00
Price To Sales (TTM)
41.92
Price To Book (MRQ)
9.58
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.49
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
23.40
Return on Equity (TTM)
15.92

Latest News

Latest News

BRIEF-Walvax Biotechnology's Prelim 2017 Net Loss Of 535.02 Mln Yuan

* SAYS PRELIM 2017 NET LOSS OF 535.02 MILLION YUAN ($84.83 million) VERSUS NET PROFIT OF 70.46 MILLION YUAN YEAR AGO Source text in Chinese: http://bit.ly/2ETkN1v Further company coverage: ($1 = 6.3070 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Walvax Biotechnology Revises 2017 Results, Sees 2017 Net Loss At 533.5-538.5 Mln Yuan

* SAYS IT REVISES 2017 RESULTS, SEES 2017 NET LOSS AT 533.5-538.5 MILLION YUAN ($82.63-$83.40 million)VERSUS 70.46 MILLION YUAN NET PROFIT YEAR AGO Source text in Chinese: http://bit.ly/2ARBVC9 Further company coverage: ($1 = 6.4568 Chinese yuan renminbi) (Reporting by Hong...

BRIEF-Walvax Biotechnology unit gets approval for clinical trail on new drug GB223 injection

* Says its controlling biotech unit got approval for clinical trail of new drug GB223 injection, which is used for treatment of osteoporosis, bone metastasis of solid tumor and other related diseases

BRIEF-Walvax Biotechnology to sell Shanghai-based pharma-tech unit for 10 mln yuan

* Says it plans to sell 100 percent stake in Shanghai-based pharma-tech unit for 10 million yuan

BRIEF-Walvax Biotechnology to sell 100 pct stake in Jiangsu-based biotech unit

* Says it plans to sell 100 percent stake in a Jiangsu-based biotechnology unit to a Guangzhou-based biotechnology firm (buyer) for 90 million yuan, and to transfer split influenza virus vaccine related project to buyer at the same time

BRIEF-Limited partnership to invest 650 mln yuan in Walvax Biotechnology's unit

* Says a Tianjin-based limited partnership plans to invest 650 million yuan in co's biotechnology unit

BRIEF-Walvax Biotechnology sees FY 2017 net profit down 27 pct to 57 pct

* Sees FY 2017 net profit to decrease by 27 percent to 57 percent, or to be 30 million yuan to 51 million yuan

BRIEF-Investment fund to invest 600 mln yuan in Walvax Biotechnology's unit

* Says an investment fund to invest 600 million yuan ($91.07 million) in company's unit

BRIEF-Walvax Biotechnology sees FY 2017 H1 net loss to be 41 mln yuan to 46 mln yuan

* Sees FY 2017 H1 net loss to be 41 million yuan to 46 million yuan, compared to net profit of FY 2016 H1(161.9 million yuan)

BRIEF-Walvax Biotechnology sees FY 2017 Q1 net loss to be 25 mln yuan to 30 mln yuan

* Sees FY 2017 Q1 net loss to be 25 million yuan to 30 million yuan

BRIEF-Walvax Biotechnology returns to net profit in 2016

* Says prelim 2016 net profit of 72.2 million yuan ($10.51 million) versus net loss of 840.9 million yuan year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up